M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...
A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.
Leucine-rich repeat–containing protein 15 (LRRC15) is a cell surface protein that has emerged as a significant biomarker in cancer biology. This protein is minimally expressed in normal healthy tissue ...
Drugmaker Bristol-Myers Squibb Co (BMY.N) will globally develop, make and sell a therapy being tested by New York's ...
The U.S. Food and Drug Administration on Friday approved Roche's under-the-skin injection to treat patients with multiple ...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced ...
Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...
A study led by André Veillette, a researcher at the Montreal Clinical Research Institute (IRCM) and a professor in the ...
According to the latest analysis by DataM Intelligence, the Next-Generation Multiple Myeloma Therapies Market Size was valued ...
Lausanne, Switzerland, November 4, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported ...
Pancreatic cancer is notoriously hard to treat and often resists the most advanced immunotherapies. Northwestern Medicine scientists have uncovered a novel explanation for that resistance: Pancreatic ...
Study reveals how pancreatic tumors evade immunity using a sugar disguise, and how a new antibody restores immunity in mice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback